Skip to content
Brea C. Lipe, M.D.

Brea C. Lipe, M.D.

Cancer

UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

Contact

About Me

I am the clinical director of Wilmot's multiple myeloma program, and in the laboratory and in the clinic, I am focused on improving the care of patients with multiple myeloma and other plasma cell dyscrasias. Treatment options and our understanding of multiple myeloma have changed dramatically in th...
I am the clinical director of Wilmot's multiple myeloma program, and in the laboratory and in the clinic, I am focused on improving the care of patients with multiple myeloma and other plasma cell dyscrasias. Treatment options and our understanding of multiple myeloma have changed dramatically in the last 10 years. The rapid pace of change, intrinsic disease complexity, and the ability to impact patient lives still leaves me amazed and humbled every day.

I believe that it's important to know my patients as individuals to understand the situational circumstance and personality that drives their treatment goals. Multiple myeloma is a lifelong journey and a strong partnership with my patients is essential to achieving the best quality of care. I have a strong interest in clinical research and like to offer my patients a variety of clinical trial options and treatments based on the most recent data. I have a dedicated support team, so that we can offer patients a team with real myeloma-specific expertise.

In my research laboratory, I am particularly interested in understanding the mechanisms that allow multiple myeloma to develop. I have created a system that lets us mimic in a laboratory, the growth of cancer cells that become multiple myeloma. By studying disease progression, my ultimate goal is to develop therapies to prevent multiple myeloma.

Outside of work, I love to grow things -- flowers, vegetables, orchids, animals, children. I have gotten some of my best gardening tips from my patients.

Conditions I treat:

- Multiple myeloma
- Other plasma cell disorders

Faculty Appointments

Professor - Department of Medicine, Hematology/Oncology (SMD)

Credentials

Residency & Fellowship

Fellowship, Hematology & Oncology, Dartmouth-Hitchcock Medical Center. 2008 - 2011

Residency, Internal Medicine, Dartmouth-Hitchcock Medical Center. 2006 - 2008

Internship, Internal Medicine, Dartmouth-Hitchcock Medical Center. 2005 - 2006

Education

MD | Albany Medical College. 2005

Awards

Leadership Academy. 2017

Department of Internal Medicine OSARM Faculty Incubator Scholar. 2011

Clinical Research Training Institute Clinical Scholar for ASH. 2011

Award for Excellence in Teaching. 2009

Award for Excellence in Teaching. 2007

Frank C. Knievel Scholarship Award. 2001 - 2005

First Generation Diversity Scholarship. 1996 - 2001

Research

In my research laboratory, I am particularly interested in understanding the mechanisms that allow multiple myeloma to develop. I have created a system that lets us mimic in a laboratory, the growth of cancer cells that become multiple myeloma. By studying disease progression, my ultimate goal is ...
In my research laboratory, I am particularly interested in understanding the mechanisms that allow multiple myeloma to develop. I have created a system that lets us mimic in a laboratory, the growth of cancer cells that become multiple myeloma. By studying disease progression, my ultimate goal is to develop therapies to prevent multiple myeloma.

Clinical Trials

A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance

Lead Researcher: Brea C Lipe

This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are considered frail ...

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

Lead Researcher: Brea C Lipe

The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).

ULAB-16115 A program for following disease progression in Multiple Myeloma

Lead Researcher: Brea C Lipe

The purpose of this study is to collect clinical data along with bone marrow aspirate samples to see if there is a way to determine which patients are more or less likely to experience disease progression. This study will involve identifying differe...

Publications

Journal Articles

Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies: Guideline From the College of American Pathologists in Collaboration With the American Association for Clinical Chemistry and the American Society for Clinical Pathology.

Keren DF, Bocsi G, Billman BL, Etzell J, Faix JD, Kumar S, Lipe B, McCudden C, Montgomery R, Murray DL, Rai AJ, Redondo TC, Souter L, Ventura CB, Ansari MQ

Archives of pathology & laboratory medicine.. 2021 August 4 Epub 08/04/2021.

Bisphosphonates for delivering drugs to bone.

Sun S, Tao J, Sedghizadeh PP, Cherian P, Junka AF, Sodagar E, Xing L, Boeckman RK, Srinivasan V, Yao Z, Boyce BF, Lipe B, Neighbors JD, Russell G, McKenna CE, Ebetino FH

British journal of pharmacology.. 2020 September 2 Epub 09/02/2020.

Management of Frail Older Adults with Newly Diagnosed Multiple Myeloma - Moving Toward a Personalized Approach.

Grant SJ, Lipe B

Clinical lymphoma, myeloma & leukemia.. 2020 September 20 Suppl 1 :S76-S80. Epub 1900 01 01.

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma

Gasparetto, C; Lentzsch, S; Schiller, G; Callander, N; Tuchman, S; Chen, C; White, D; Kotb, R; Sutherland, H; Sebag, M; Baljevic, M; Bensinger, W; LeBlanc, R; Venner, C; Bahlis, N; Rossi, A; Biran, N; Sheehan, H; Saint-Martin, J; Van Domelen, D; Kai, K; Shah, J; Shacham, S; Kauffman, M; Lipe, B.

eJHaem. 2020; .

Integrating Touchscreen-Based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma to Drive Personalized Treatment Decisions.

Nathwani N, Kurtin SE, Lipe B, Mohile SG, Catamero DD, Wujcik D, Birchard K, Davis A, Dudley W, Stricker CT, Wildes TM

Journal of oncology practice. 2019 November 25 :JOP1900208. Epub 11/25/2019.

Results of the First Clinical Study in Humans That Combines Hyperbaric Oxygen Pretreatment with Autologous Peripheral Blood Stem Cell Transplantation.

Lipe B, Divine C, Abhyankar S, Singh AK, Ganguly S, Lin TL, Baran A, Cantilena AR, Bhatti S, Shune L, Abdelhakim H, McGuirk J, Allin D, Aljitawi OS

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2019 September 25 (9):1713-1719. Epub 06/03/2019.

A review of thrombotic microangiopathies in multiple myeloma.

Lipe B, Passero FC, Gleber C, Portuguese AJ

Leukemia research.. 2019 July 2985 :106195. Epub 07/29/2019.

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.

Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, García-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S

The Lancet. Oncology.. 2019 June 20 (6):e302-e312. Epub 1900 01 01.

Decellularized Wharton jelly matrix: a biomimetic scaffold for ex vivo hematopoietic stem cell culture.

Li D, Chiu G, Lipe B, Hopkins RA, Lillis J, Ashton JM, Paul S, Aljitawi OS

Blood advances.. 2019 April 93 (7):1011-1026. Epub 1900 01 01.

Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline.

Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, Kumar S, Lacy M, Lipe B, Little RF, Nikonova A, Omel J, Peswani N, Prica A, Raje N, Seth R, Vesole DH, Walker I, Whitley A, Wildes TM, Wong SW, Martin T

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2019 April 1 :JCO1802096. Epub 04/01/2019.

Hemophagocytic Lymphohistiocytosis in a Patient With Multiple Myeloma.

Hsu CM, Bennett JM, Lipe B

Clinical lymphoma, myeloma & leukemia.. 2019 January 19 (1):e29-e32. Epub 09/05/2018.

Application of risk factors for venous thromboembolism in patients with multiple myeloma starting chemotherapy, a real-world evaluation.

Baker HA, Brown AR, Mahnken JD, Shireman TI, Webb CE, Lipe BC

Cancer medicine. 2019 January 8 (1):455-462. Epub 12/25/2018.

Induction Therapy for Newly Diagnosed Multiple Myeloma.

Paul B, Lipe B, Ocio EM, Usmani SZ

American Society of Clinical Oncology educational book. 2019 January 39 :e176-e186. Epub 05/17/2019.

Induction Therapy for Newly Diagnosed Multiple Myeloma.

Paul, B; Lipe, B; Ocio, EM; Usmani, SZ.

Am Soc Clin Oncol Educ Book. 2019; 39: e176-e186.

Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous deletion.

Portuguese AJ, Lipe B

Blood advances.. 2018 December 112 (23):3443-3446. Epub 1900 01 01.

A novel extracellular matrix-based leukemia model supports leukemia cells with stem cell-like characteristics.

Li D, Lin TL, Lipe B, Hopkins RA, Shinogle H, Aljitawi OS

Leukemia research.. 2018 September 72 :105-112. Epub 08/16/2018.

Correlation between markers of bone metabolism and vitamin D levels in patients with monoclonal gammopathy of undetermined significance (MGUS).

Lipe B, Kambhampati S, Veldhuizen PV, Yacoub A, Aljitawi O, Mikhael J

Blood cancer journal.. 2017 December 147 (12):646. Epub 12/14/2017.

Combined deficiency of factor V and factor VIII: management during cardiothoracic surgery.

Howard C, Lipe B

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.. 2017 April 28 (3):267-268. Epub 1900 01 01.

Erythropoietin modulation is associated with improved homing and engraftment after umbilical cord blood transplantation.

Aljitawi OS, Paul S, Ganguly A, Lin TL, Ganguly S, Vielhauer G, Capitano ML, Cantilena A, Lipe B, Mahnken JD, Wise A, Berry A, Singh AK, Shune L, Lominska C, Abhyankar S, Allin D, Laughlin M, McGuirk JP, Broxmeyer HE

Blood.. 2016 December 22128 (25):3000-3010. Epub 10/19/2016.

The role of maintenance therapy in multiple myeloma.

Lipe B, Vukas R, Mikhael J

Blood cancer journal.. 2016 October 216 (10):e485. Epub 10/21/2016.

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.

Gupta N, Hanley MJ, Harvey RD, Badros A, Lipe B, Kukreti V, Berdeja J, Yang H, Hui AM, Qian M, Zhang X, Venkatakrishnan K, Chari A

British journal of haematology.. 2016 September 174 (5):748-59. Epub 05/16/2016.

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P,

The New England journal of medicine.. 2016 August 25375 (8):754-66. Epub 1900 01 01.

Monoclonal Gammopathy of Undetermined Significance (MGUS).

Lipe, B; Drurie, B.

Pocket Guide for American Society of Hematology. 2016; .

Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211.

Usmani SZ, Sexton R, Ailawadhi S, Shah JJ, Valent J, Rosenzweig M, Lipe B, Zonder JA, Fredette S, Durie B, Hoering A, Bartlett B, Orlowski RZ

Blood cancer journal.. 2015 August 75 :e334. Epub 08/07/2015.

IgG kappa monoclonal gammopathy of undetermined significance presenting as acquired type III Von Willebrand syndrome.

Howard CR, Lin TL, Cunningham MT, Lipe BC

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.. 2014 September 25 (6):631-3. Epub 1900 01 01.

Toward personalized medicine in acute myelogenous leukemia.

Lin, TL; Lipe, BC.

Personalized Medicine. 2013; 10(6): 427-430.

Bone marrow transplant for multiple myeloma: impact of distance from the transplant center.

Lipe BC, Lansigan F, Gui J, Meehan K

Clinical advances in hematology & oncology : H&O.. 2012 January 10 (1):28-32. Epub 1900 01 01.

Granulocytic sarcoma 12 years following allogeneic marrow transplant for AML.

Lipe BC, Cogbill E, Hill J, Meehan K

Clinical advances in hematology & oncology : H&O.. 2011 December 9 (12):948-51. Epub 1900 01 01.

Deficiencies of natural anticoagulants, protein C, protein S, and antithrombin.

Lipe B, Ornstein DL

Circulation.. 2011 October 4124 (14):e365-8. Epub 1900 01 01.

Von Willebrand disease in pregnancy.

Lipe BC, Dumas MA, Ornstein DL

Hematology/oncology clinics of North America.. 2011 April 25 (2):335-58, viii. Epub 1900 01 01.

Lipoprotein lipase links dietary fat to solid tumor cell proliferation.

Kuemmerle NB, Rysman E, Lombardo PS, Flanagan AJ, Lipe BC, Wells WA, Pettus JR, Froehlich HM, Memoli VA, Morganelli PM, Swinnen JV, Timmerman LA, Chaychi L, Fricano CJ, Eisenberg BL, Coleman WB, Kinlaw WB

Molecular cancer therapeutics.. 2011 March 10 (3):427-36. Epub 01/31/2011.

An overview of angiotensin-converting enzyme inhibitors in the treatment of hypertension.

Weber MA

The Journal of the American Osteopathic Association.. 1987 February 87 (2 Suppl):175-80. Epub 1900 01 01.